+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Gabapentin Market by Route of Administration, Formulation, Dosage Form, Distribution Channel, End User, Indication - Global Forecast to 2030- Product Image
Gabapentin Market by Route of Administration, Formulation, Dosage Form, Distribution Channel, End User, Indication - Global Forecast to 2030- Product Image
Sale

Gabapentin Market by Route of Administration, Formulation, Dosage Form, Distribution Channel, End User, Indication - Global Forecast to 2030

  • PDF Icon

    Report

  • 196 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6016490
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Gabapentin Market grew from USD 2.32 billion in 2024 to USD 2.43 billion in 2025. It is expected to continue growing at a CAGR of 4.39%, reaching USD 3.01 billion by 2030.

Setting the Stage for Gabapentin’s Market Landscape

The gabapentin market has emerged as a focal point for pharmaceutical stakeholders worldwide, driven by its multifaceted applications and evolving regulatory landscapes. As a cornerstone therapy for nerve-related conditions, gabapentin’s journey encompasses both clinical breakthroughs and market-driven innovations. In recent years, generic entrants have reshaped competitive dynamics, compelling established players to optimize manufacturing efficiencies and diversify distribution channels. Meanwhile, patient advocacy groups and prescribers continue to influence access policies, underscoring the critical interplay between medical need and market availability. This section provides an essential foundation, setting the stage for deeper exploration of transformative trends and strategic considerations that define the current gabapentin ecosystem.

Unprecedented Transformations Reshaping the Gabapentin Arena

In recent cycles, the gabapentin landscape has undergone unprecedented metamorphosis, fueled by breakthroughs in delivery technologies and shifts in prescriber preferences. Technological advancements have refined oral solution formulations, offering enhanced bioavailability and patient adherence, while novel extended release tablets address chronic pain management with greater dosing convenience. Simultaneously, the rise of digital health platforms has transformed patient engagement, enabling remote titration and monitoring that bolster therapeutic outcomes. These developments coincide with a surge in off-label use for conditions such as restless leg syndrome, prompting regulatory bodies to reassess label expansions. As manufacturing networks embrace modular capabilities and supply chain transparency becomes paramount, stakeholders must adapt swiftly to maintain resilience and seize emerging opportunities.

Assessing the Ripple Effects of 2025 U.S. Tariff Changes

The implementation of new tariff regimes in 2025 has introduced a complex set of variables affecting gabapentin’s supply chain and pricing structures. Import duties on active pharmaceutical ingredients have elevated production costs for firms reliant on overseas manufacturers, particularly those sourcing raw materials from Asia-Pacific hubs. In response, several key players have pursued nearshoring strategies, relocating intermediate processing closer to end markets to mitigate exposure to tariff volatility. At the same time, wholesalers and distributors are recalibrating inventory models to avoid stockouts while managing working capital pressures. Repercussions extend to patient access, with payers assessing formulary adjustments to contain budget impacts. Understanding these cumulative tariff effects is pivotal for forecasting procurement strategies and negotiating value-based contracts moving forward.

Decoding Market Segmentation to Illuminate Growth Pathways

A granular examination of the market through multiple segmentation lenses reveals distinct pockets of growth and innovation. By route of administration, oral delivery remains dominant, with capsule and tablet offerings driving volume, while parenteral formulations capture specialized hospital demand for acute neuropathic pain interventions. Within formulation dynamics, generics continue to command substantial share, yet branded variants maintain relevance via value-added features such as abuse-deterrent matrices. Dosage form segmentation further uncovers contrast between hard gelatin capsules favored for rapid onset and soft gelatin alternatives optimized for controlled release, alongside tablets engineered for immediate versus extended therapeutic profiles. Distribution channels span the spectrum from hospital pharmacies that prioritize injectable supplies to burgeoning online pharmacies catering to home care patients, complemented by traditional retail pharmacy networks ensuring broad geographic access. End users range from specialized clinics administering intravenous protocols to home care settings where self-administration is paramount, with hospitals orchestrating inpatient regimens. Indication-driven analysis spotlights epilepsy as an established volume driver, while neuropathic pain subsegments-diabetic neuropathy and postherpetic neuralgia-exhibit robust growth potential, and opportunities in restless leg syndrome underscore portfolio diversification strategies.

Unearthing Regional Dynamics Driving Gabapentin Uptake

Regional performance patterns demonstrate heterogeneous trajectories across global markets. In the Americas, well-established reimbursement frameworks support high treatment penetration, though payer skepticism over long-term utilization prompts lifecycle management tactics. Conversely, Europe, Middle East & Africa reflects a mosaic of regulatory regimes, where centralized procurement in certain European markets contrasts with decentralized tendering in Middle Eastern and African territories facing infrastructural constraints. Stakeholders in this region navigate currency fluctuations and evolving health policy reforms that influence market entry plans. The Asia-Pacific landscape offers a dual narrative: mature economies like Japan and Australia showcase growing uptake of extended release formulations, while emerging markets in Southeast Asia and South Asia underscore cost-sensitivity and preference for generics. Across all regions, strategic alliances and localized manufacturing partnerships remain critical for scaling distribution networks and aligning with diverse healthcare delivery models.

Profiling Industry Pioneers Steering Gabapentin Innovation

A cohort of leading pharmaceutical and generics manufacturers anchors the gabapentin market, each leveraging unique competencies to fortify their positions. Established innovators continue to invest in novel delivery systems and branded line extensions, harnessing proprietary technologies to differentiate their offerings. Meanwhile, specialized generic firms capitalize on process optimization and low-cost production to secure supply agreements with large-scale distributors. Collaborations between mid-sized players and contract development organizations are accelerating access to parenteral formats, while integrated pharma entrants with robust commercial infrastructures are expanding direct-to-consumer digital outreach. The competitive landscape is further nuanced by strategic acquisitions that broaden product pipelines and geographic footprints. Observing these corporate maneuvers provides critical perspective on how capability portfolios are evolving to meet multifaceted market demands.

Strategic Imperatives for Stakeholders to Seize Opportunities

Industry leaders seeking to capitalize on gabapentin’s momentum must adopt a strategic playbook focused on agility and differentiation. First, optimizing manufacturing footprints by embracing modular, single-use technologies can reduce lead times and minimize exposure to tariff disruptions. Second, investing in patient-centric delivery formats-such as extended release tablets and abuse-deterrent capsules-will address evolving prescriber and payer expectations. Third, forging alliances with digital health providers to embed adherence monitoring into therapy regimens can drive real-world evidence and support value-based contracting. Fourth, tailoring market entry strategies through region-specific partnerships ensures that regulatory complexities and reimbursement landscapes are navigated effectively. Finally, establishing clear brand positioning that highlights clinical benefits and safety profiles will reinforce stakeholder confidence and foster long-term loyalty. Collectively, these imperatives will empower decision-makers to stay ahead of competitive shifts and secure sustainable growth.

Rigorous Research Approach Underpinning Analysis

Our analysis is grounded in a blend of qualitative and quantitative research methodologies designed to yield robust, unbiased insights. Primary research encompassed in-depth interviews with key opinion leaders, including neurologists, pain management specialists, and procurement executives, to capture firsthand perspectives on prescribing trends and supply chain dynamics. Secondary research involved extensive review of regulatory filings, patent landscapes, and company disclosures to validate emerging technologies and competitive strategies. Market dynamics were further enriched by data triangulation, integrating intelligence from pharmaceutical distributors, clinical trial registries, and healthcare databases. Rigorous data cleansing and validation protocols were applied throughout to ensure consistency and accuracy. This methodological framework underpins the credibility of our findings and supports informed decision-making by industry stakeholders.

Synthesizing Insights on Gabapentin’s Future Trajectory

The collective insights presented herein spotlight a market at the nexus of clinical innovation, regulatory evolution, and commercial imperative. From the nuanced segmentation analysis revealing targeted growth vectors to the strategic recommendations designed to navigate tariff-induced headwinds, stakeholders are equipped with a holistic understanding of gabapentin’s trajectory. Anticipated developments in personalized medicine, coupled with next-generation delivery modalities, suggest a continued expansion of therapeutic use cases. However, success will hinge on the ability to align product innovation with supply chain resilience and stakeholder collaboration. By synthesizing these diverse facets, this report lays the groundwork for proactive strategies that will shape the competitive landscape in the years ahead.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Route Of Administration
    • Oral
    • Parenteral
  • Formulation
    • Branded
    • Generic
  • Dosage Form
    • Capsules
      • Hard Gelatin
      • Soft Gelatin
    • Oral Solution
    • Tablets
      • Extended Release
      • Immediate Release
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
  • End User
    • Clinics
    • Home Care
    • Hospitals
  • Indication
    • Epilepsy
    • Neuropathic Pain
      • Diabetic Neuropathy
      • Postherpetic Neuralgia
    • Restless Leg Syndrome
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Apotex Inc.
  • Sandoz International GmbH
  • Sun Pharmaceutical Industries Ltd.
  • Cipla Ltd.
  • Zydus Lifesciences Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Alembic Pharmaceuticals Ltd.
  • Lupin Ltd.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Gabapentin Market, by Route of Administration
8.1. Introduction
8.2. Oral
8.3. Parenteral
9. Gabapentin Market, by Formulation
9.1. Introduction
9.2. Branded
9.3. Generic
10. Gabapentin Market, by Dosage Form
10.1. Introduction
10.2. Capsules
10.2.1. Hard Gelatin
10.2.2. Soft Gelatin
10.3. Oral Solution
10.4. Tablets
10.4.1. Extended Release
10.4.2. Immediate Release
11. Gabapentin Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.3. Online Pharmacy
11.4. Retail Pharmacy
12. Gabapentin Market, by End User
12.1. Introduction
12.2. Clinics
12.3. Home Care
12.4. Hospitals
13. Gabapentin Market, by Indication
13.1. Introduction
13.2. Epilepsy
13.3. Neuropathic Pain
13.3.1. Diabetic Neuropathy
13.3.2. Postherpetic Neuralgia
13.4. Restless Leg Syndrome
14. Americas Gabapentin Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Gabapentin Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Gabapentin Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Teva Pharmaceutical Industries Ltd.
17.3.2. Viatris Inc.
17.3.3. Apotex Inc.
17.3.4. Sandoz International GmbH
17.3.5. Sun Pharmaceutical Industries Ltd.
17.3.6. Cipla Ltd.
17.3.7. Zydus Lifesciences Ltd.
17.3.8. Torrent Pharmaceuticals Ltd.
17.3.9. Alembic Pharmaceuticals Ltd.
17.3.10. Lupin Ltd.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. GABAPENTIN MARKET MULTI-CURRENCY
FIGURE 2. GABAPENTIN MARKET MULTI-LANGUAGE
FIGURE 3. GABAPENTIN MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL GABAPENTIN MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL GABAPENTIN MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL GABAPENTIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL GABAPENTIN MARKET SIZE, BY FORMULATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL GABAPENTIN MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 12. GLOBAL GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL GABAPENTIN MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL GABAPENTIN MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL GABAPENTIN MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 18. GLOBAL GABAPENTIN MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS GABAPENTIN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS GABAPENTIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES GABAPENTIN MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES GABAPENTIN MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. GABAPENTIN MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. GABAPENTIN MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. GABAPENTIN MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL GABAPENTIN MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL GABAPENTIN MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL GABAPENTIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL GABAPENTIN MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL GABAPENTIN MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL GABAPENTIN MARKET SIZE, BY BRANDED, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL GABAPENTIN MARKET SIZE, BY GENERIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL GABAPENTIN MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL GABAPENTIN MARKET SIZE, BY HARD GELATIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL GABAPENTIN MARKET SIZE, BY SOFT GELATIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL GABAPENTIN MARKET SIZE, BY ORAL SOLUTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL GABAPENTIN MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL GABAPENTIN MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL GABAPENTIN MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL GABAPENTIN MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL GABAPENTIN MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL GABAPENTIN MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL GABAPENTIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL GABAPENTIN MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL GABAPENTIN MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL GABAPENTIN MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL GABAPENTIN MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL GABAPENTIN MARKET SIZE, BY DIABETIC NEUROPATHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL GABAPENTIN MARKET SIZE, BY POSTHERPETIC NEURALGIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL GABAPENTIN MARKET SIZE, BY RESTLESS LEG SYNDROME, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS GABAPENTIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS GABAPENTIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES GABAPENTIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES GABAPENTIN MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 57. CANADA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 58. CANADA GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 59. CANADA GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 60. CANADA GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2030 (USD MILLION)
TABLE 61. CANADA GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 62. CANADA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 63. CANADA GABAPENTIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 64. CANADA GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 65. CANADA GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 66. MEXICO GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 67. MEXICO GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 68. MEXICO GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 69. MEXICO GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2030 (USD MILLION)
TABLE 70. MEXICO GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 71. MEXICO GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 72. MEXICO GABAPENTIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 73. MEXICO GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 74. MEXICO GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 75. BRAZIL GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 76. BRAZIL GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 77. BRAZIL GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 78. BRAZIL GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2030 (USD MILLION)
TABLE 79. BRAZIL GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 80. BRAZIL GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL GABAPENTIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 84. ARGENTINA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 85. ARGENTINA GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA GABAPENTIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 93. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 94. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 95. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 96. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2030 (USD MILLION)
TABLE 97. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 99. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 103. UNITED KINGDOM GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 104. UNITED KINGDOM GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 105. UNITED KINGDOM GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 106. UNITED KINGDOM GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2030 (USD MILLION)
TABLE 107. UNITED KINGDOM GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 108. UNITED KINGDOM GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 109. UNITED KINGDOM GABAPENTIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 110. UNITED KINGDOM GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 111. UNITED KINGDOM GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 112. GERMANY GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 113. GERMANY GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 114. GERMANY GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 115. GERMANY GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2030 (USD MILLION)
TABLE 116. GERMANY GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 117. GERMANY GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 118. GERMANY GABAPENTIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 119. GERMANY GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 120. GERMANY GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 121. FRANCE GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 122. FRANCE GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 123. FRANCE GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 124. FRANCE GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2030 (USD MILLION)
TABLE 125. FRANCE GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 126. FRANCE GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 127. FRANCE GABAPENTIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 128. FRANCE GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 129. FRANCE GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 130. RUSSIA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 131. RUSSIA GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 132. RUSSIA GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 133. RUSSIA GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2030 (USD MILLION)
TABLE 134. RUSSIA GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 135. RUSSIA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 136. RUSSIA GABAPENTIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 137. RUSSIA GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 138. RUSSIA GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 139. ITALY GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 140. ITALY GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 141. ITALY GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 142. ITALY GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2030 (USD MILLION)
TABLE 143. ITALY GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 144. ITALY GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 145. ITALY GABAPENTIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 146. ITALY GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 147. ITALY GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 148. SPAIN GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 149. SPAIN GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 150. SPAIN GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 151. SPAIN GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2030 (USD MILLION)
TABLE 152. SPAIN GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 153. SPAIN GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 154. SPAIN GABAPENTIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 155. SPAIN GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 156. SPAIN GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 157. UNITED ARAB EMIRATES GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 158. UNITED ARAB EMIRATES GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 159. UNITED ARAB EMIRATES GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 160. UNITED ARAB EMIRATES GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2030 (USD MILLION)
TABLE 161. UNITED ARAB EMIRATES GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 162. UNITED ARAB EMIRATES GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 163. UNITED ARAB EMIRATES GABAPENTIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 164. UNITED ARAB EMIRATES GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 165. UNITED ARAB EMIRATES GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 166. SAUDI ARABIA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 167. SAUDI ARABIA GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 168. SAUDI ARABIA GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 169. SAUDI ARABIA GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2030 (USD MILLION)
TABLE 170. SAUDI ARABIA GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 171. SAUDI ARABIA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 172. SAUDI ARABIA GABAPENTIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 173. SAUDI ARABIA GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 174. SAUDI ARABIA GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 175. SOUTH AFRICA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 176. SOUTH AFRICA GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 177. SOUTH AFRICA GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 178. SOUTH AFRICA GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2030 (USD MILLION)
TABLE 179. SOUTH AFRICA GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 180. SOUTH AFRICA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 181. SOUTH AFRICA GABAPENTIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 182. SOUTH AFRICA GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 183. SOUTH AFRICA GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 184. DENMARK GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 185. DENMARK GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 186. DENMARK GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 187. DENMARK GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2030 (USD MILLION)
TABLE 188. DENMARK GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 189. DENMARK GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 190. DENMARK GABAPENTIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 191. DENMARK GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 192. DENMARK GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 193. NETHERLANDS GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 194. NETHERLANDS GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 195. NETHERLANDS GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 196. NETHERLANDS GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2030 (USD MILLION)
TABLE 197. NETHERLANDS GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 198. NETHERLANDS GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 199. NETHERLANDS GABAPENTIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 200. NETHERLANDS GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 201. NETHERLANDS GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 202. QATAR GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 203. QATAR GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 204. QATAR GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 205. QATAR GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2030 (USD MILLION)
TABLE 206. QATAR GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 207. QATAR GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 208. QATAR GABAPENTIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 209. QATAR GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 210. QATAR GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 211. FINLAND GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 212. FINLAND GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 213. FINLAND GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 214. FINLAND GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2030 (USD MILLION)
TABLE 215. FINLAND GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 216. FINLAND GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 217. FINLAND GABAPENTIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 218. FINLAND GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 219. FINLAND GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 220. SWEDEN GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 221. SWEDEN GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 222. SWEDEN GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 223. SWEDEN GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2030 (USD MILLION)
TABLE 224. SWEDEN GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 225. SWEDEN GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 226. SWEDEN GABAPENTIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 227. SWEDEN GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 228. SWEDEN GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 229. NIGERIA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 230. NIGERIA GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 231. NIGERIA GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 232. NIGERIA GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2030 (USD MILLION)
TABLE 233. NIGERIA GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 234. NIGERIA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 235. NIGERIA GABAPENTIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 236. NIGERIA GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 237. NIGERIA GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 238. EGYPT GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 239. EGYPT GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 240. EGYPT GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 241. EGYPT GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2030 (USD MILLION)
TABLE 242. EGYPT GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 243. EGYPT GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 244. EGYPT GABAPENTIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 245. EGYPT GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 246. EGYPT GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 247. TURKEY GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 248. TURKEY GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 249. TURKEY GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 250. TURKEY GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2030 (USD MILLION)
TABLE 251. TURKEY GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 252. TURKEY GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 253. TURKEY GABAPENTIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 254. TURKEY GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 255. TURKEY GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 256. ISRAEL GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 257. ISRAEL GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 258. ISRAEL GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 259. ISRAEL GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2030 (USD MILLION)
TABLE 260. ISRAEL GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 261. ISRAEL GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 262. ISRAEL GABAPENTIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 263. ISRAEL GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 264. ISRAEL GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 265. NORWAY GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 266. NORWAY GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 267. NORWAY GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 268. NORWAY GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2030 (USD MILLION)
TABLE 269. NORWAY GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 270. NORWAY GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 271. NORWAY GABAPENTIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 272. NORWAY GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 273. NORWAY GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 274. POLAND GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 275. POLAND GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 276. POLAND GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 277. POLAND GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2030 (USD MILLION)
TABLE 278. POLAND GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 279. POLAND GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 280. POLAND GABAPENTIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 281. POLAND GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 282. POLAND GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 283. SWITZERLAND GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 284. SWITZERLAND GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 285. SWITZERLAND GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 286. SWITZERLAND GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2030 (USD MILLION)
TABLE 287. SWITZERLAND GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 288. SWITZERLAND GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 289. SWITZERLAND GABAPENTIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 290. SWITZERLAND GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 291. SWITZERLAND GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 292. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 293. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 294. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 295. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2030 (USD MILLION)
TABLE 296. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 297. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 298. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 299. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 300. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 301. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 302. CHINA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 303. CHINA GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 304. CHINA GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 305. CHINA GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2030 (USD MILLION)
TABLE 306. CHINA GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 307. CHINA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 308. CHINA GABAPENTIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 309. CHINA GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 310. CHINA GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 311. INDIA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 312. INDIA GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 313. INDIA GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 314. INDIA GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2030 (USD MILLION)
TABLE 315. INDIA GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 316. INDIA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 317. INDIA GABAPENTIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 318. INDIA GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 319. INDIA GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 320. JAPAN GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 321. JAPAN GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 322. JAPAN GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 323. JAPAN GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2030 (USD MILLION)
TABLE 324. JAPAN GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 325. JAPAN GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 326. JAPAN GABAPENTIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 327. JAPAN GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 328. JAPAN GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 329. AUSTRALIA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 330. AUSTRALIA GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 331. AUSTRALIA GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 332. AUSTRALIA GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2030 (USD MILLION)
TABLE 333. AUSTRALIA GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 334. AUSTRALIA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 335. AUSTRALIA GABAPENTIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 336. AUSTRALIA GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 337. AUSTRALIA GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 338. SOUTH KOREA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 339. SOUTH KOREA GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 340. SOUTH KOREA GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 341. SOUTH KOREA GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2030 (USD MILLION)
TABLE 342. SOUTH KOREA GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 343. SOUTH KOREA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 344. SOUTH KOREA GABAPENTIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 345. SOUTH KOREA GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 346. SOUTH KOREA GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 347. INDONESIA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 348. INDONESIA GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 349. INDONESIA GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 350. INDONESIA GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2030 (USD MILLION)
TABLE 351. INDONESIA GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 352. INDONESIA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 353. INDONESIA GABAPENTIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 354. INDONESIA GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 355. INDONESIA GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 356. THAILAND GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 357. THAILAND GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 358. THAILAND GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 359. THAILAND GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2030 (USD MILLION)
TABLE 360. THAILAND GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 361. THAILAND GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 362. THAILAND GABAPENTIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 363. THAILAND GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 364. THAILAND GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 365. PHILIPPINES GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 366. PHILIPPINES GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 367. PHILIPPINES GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 368. PHILIPPINES GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2030 (USD MILLION)
TABLE 369. PHILIPPINES GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 370. PHILIPPINES GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 371. PHILIPPINES GABAPENTIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 372. PHILIPPINES GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 373. PHILIPPINES GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 374. MALAYSIA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 375. MALAYSIA GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 376. MALAYSIA GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 377. MALAYSIA GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2030 (USD MILLION)
TABLE 378. MALAYSIA GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 379. MALAYSIA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 380. MALAYSIA GABAPENTIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 381. MALAY

Companies Mentioned

The companies profiled in this Gabapentin market report include:
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Apotex Inc.
  • Sandoz International GmbH
  • Sun Pharmaceutical Industries Ltd.
  • Cipla Ltd.
  • Zydus Lifesciences Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Alembic Pharmaceuticals Ltd.
  • Lupin Ltd.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages196
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 2.43 Billion
Forecasted Market Value ( USD ) by 2030 $ 3.01 Billion
Compound Annual Growth Rate4.3%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Gabapentin Market Size, Share & Trends Analysis Report By Dosage Form, By Type, By Application, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Gabapentin Market Size, Share & Trends Analysis Report By Dosage Form, By Type, By Application, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 100 Pages
  • Global
From
Gabapentin - Global Strategic Business Report - Product Image

Gabapentin - Global Strategic Business Report

  • Report
  • 477 Pages
  • Global
From
Gabapentin (CAS 60142-96-3) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029 - Product Image

Gabapentin (CAS 60142-96-3) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029

  • Report
  • 50 Pages
  • Global
From
Gabapentin Enacarbil (CAS 478296-72-9) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029 - Product Image

Gabapentin Enacarbil (CAS 478296-72-9) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029

  • Report
  • 50 Pages
  • Global
From
Peripheral Neuropathic Pain - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Peripheral Neuropathic Pain - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 260 Pages
  • Global
From

About the Gabapentin Market

Gabapentin is a medication used to treat certain types of seizures and nerve pain. It is a central nervous system (CNS) drug, meaning it acts on the brain and spinal cord to produce its effects. It is used to treat epilepsy, neuropathic pain, hot flashes, and restless leg syndrome. It is also used off-label to treat anxiety and insomnia. Gabapentin is generally well-tolerated, but can cause side effects such as dizziness, drowsiness, and confusion. Gabapentin is available in both generic and brand-name forms. It is available in capsule, tablet, and oral solution forms. It is also available as an extended-release tablet, which is taken once daily. The market for Gabapentin is highly competitive, with many companies offering generic and brand-name versions of the drug. Some of the companies in the market include Pfizer, Mylan, Teva Pharmaceuticals, Sun Pharmaceuticals, and Lupin Pharmaceuticals. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.